CRDF — Cardiff Oncology Income Statement
0.000.00%
Last trade - 00:00- $187.60m
- $94.76m
- $0.68m
Annual income statement for Cardiff Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.366 | 0.359 | 0.386 | 0.488 | 0.683 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 19.5 | 29.2 | 40.3 | 45.9 | 49.3 |
| Operating Profit | -19.1 | -28.9 | -39.9 | -45.4 | -48.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.3 | -28.3 | -38.7 | -41.4 | -45.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19.3 | -28.3 | -38.7 | -41.4 | -45.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.3 | -28.3 | -38.7 | -41.4 | -45.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.6 | -28.3 | -38.7 | -41.5 | -45.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.08 | -0.725 | -0.888 | -0.928 | -0.954 |